Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.
Xinyuan Li, Chunlin Zhang, Yuhua Mei...
https://pubmed.ncbi.nlm.nih.gov/40634292/Actively Recruiting
Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-03-26
18
Participants Needed
1
Research Sites
34 weeks
Total Duration
Researchers are studying a new combined treatment using irinotecan liposomes given by intravenous injection and epirubicin given by bladder instillation for adults with non-muscle invasive bladder urothelial carcinoma that has returned after anthracycline treatment. This Phase I trial aims to find out the maximum safe dose and whether this combined approach can overcome resistance to anthracyclines. The study also explores the safety and biological effects of the treatment. Participants are assigned to one of two groups based on whether their recurrent tumor can be surgically removed by transurethral resection of bladder tumor TURBT. In Arm A unresectable tumors, patients receive irinotecan liposomes every two weeks for one month and epirubicin once a week for one month before evaluation by urologists. Those who respond may then undergo TURBT and further bladder therapy. Arm B resectable tumors involves TURBT surgery followed by immediate epirubicin instillation, then combined irinotecan liposomes and epirubicin weekly for one month, followed by monthly epirubicin for six months. Throughout the study, participants have regular clinic visits for physical exams and testing visits occur every two weeks initially and then every three months for Arm B. They keep symptom diaries to track their experience. Researchers monitor bone marrow suppression, treatment safety, tumor response, recurrence-free survival, and biological markers from tumor tissue. The total study duration includes a four-week dose-limiting toxicity phase and longer follow-up for safety and tumor recurrence.
CONDITIONS
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
X
Xin Gou, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Affiliated Hospital of Chongqing Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 month
Participants in Arm A who cannot have their tumor excised will receive neoadjuvant therapy with irinotecan liposome intravenously once every two weeks for 1 month and epirubicin instilled once a week for 1 month before TURBT surgery.
2 visits (intravenous injection every 2 weeks) and 4 visits (intravesical instillation once a week)
Duration - 1 day
Participants in Arm B who have resectable tumors will undergo TURBT surgery with immediate intravesical instillation of epirubicin within 24 hours after surgery.
1 visit (in-person surgery and instillation)
Duration - 1 month
Participants in Arm B will receive combined irinotecan liposome intravenously once every two weeks for 1 month and epirubicin intravesically once a week for 1 month during the induction phase after surgery.
2 visits (intravenous injection every 2 weeks) and 4 visits (intravesical instillation once a week)
Duration - 6 months
Participants in Arm B will continue monthly intravesical instillation of epirubicin for the next 6 months after the induction phase.
Monthly visits for epirubicin instillation
Duration - Up to 6 months
Participants in both arms will visit the clinic every 2 weeks during the first month for checkups and tests. After the first month in Arm B, visits occur every 3 months for ongoing monitoring.
Biweekly visits during first month; then quarterly visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Xinyuan Li, Chunlin Zhang, Yuhua Mei...
https://pubmed.ncbi.nlm.nih.gov/40634292/First Affiliated Hospital of Chongqing Medical University
Lead Sponsor